Many biohackers, athletes, and professionals use it with noticeable results
You dont have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease
Progressive overload should still drive your training program
Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes
As Medicare coverage expansions in 2025 and 2026 extend GLP-1 drugs to millions of older Americans for the first time, researchers and clinicians are urging a different approach for this age group: more careful baseline assessment, slower dosing, higher protein targets, and proactive monitoring for muscle loss, malnutrition, and bone density decline
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists, widely prescribed for type 2 diabetes and weight management, are known for their metabolic benefits but may have unrecognized side effects